Martinex Research Centre
Martinex Research Centre is the most recent addition to our group of companies, established in 2009, when our research department has been transformed into an independent nonprofit organization “Martinex Research Centre”. During its short existence, scientists at the centre have developed a unique method of solid-state modification of biopolymers, such as Hyaluronic Acid, and received 9 patents for it and related techniques. Permanent staff of Martinex Research Centre consists of 12 employees, six of whom hold doctorate degrees in biology, chemistry, and medicine.
Over 20 articles written by our researchers have been published in Russian scholarly journals over the past two years on a variety of topics from aesthetic medicine, to biochemistry, oncology, and nuclear therapy. We have also published a comprehensive monograph titled “Hyaluronic Acid: synthesis, properties, applications in biology and medicine”
Current efforts of Martinex Research Centre are primarily focused on developing new applications for our unique technique of solid-state biopolymer modification. So far, we have created a new class of macromolecular therapeutic compounds called “Hyalrepair”. These products contain various biological compounds attached to hyaluronic acid. Hyalrepair uses compounds only native to the human body, and no chemical agents whatsoever (potentially toxic) are used during the production of modified hyaluronic acid.
Hyalrepair is designed to treat deficiency of key metabolites or regulators within an organism. When natural biochemical equilibria are disrupted, this can lead to pathological changes. One of the effects of HA is the ability to deliver the needed compounds in natural, biologically-accessible form, and release them at a steady pace, convenient for the organism.
Primary limitation of therapeutic applications of HA has been its half-life within the organism. However, Hyalrepair successfully overcomes this setback through attachment of various metabolites onto hyaluronic acid, which increases its stability within an organism. HA is constantly broken down by hyaluronidase group of enzymes and modifying its structure makes it “less recognizable” for hyaluronidase, so the HA chains are digested slower, ensuring longer therapeutic effect and gradual release of attached compounds into the body. Various possible intra- and inter-molecular solid-state connections of other compounds to HA result in different half-lifes of the final product, allowing us to customize the drug to be metabolised faster or slower.
Other Applications of Modified Hyaluronic Acid
We have only tapped the surface of the pool of potential applications of hyaluronic acid with Hyalrepair. Among other uses, we are currently developing anti-inflammatory, anti-arthritis and anti-tumor drugs based on modified HA. Hyaluronic acid increases the effect of traditional tumor medications, allowing for a reduction of the therapeutic dosage, which reduces the toxicity of the treatment for normal non-tumor cells. Same effect can be achieved by a lower dose of the drug administered together with HA.
Martinex Research Centre participates in two federal cancer research programs on the subject of nuclear medicine. We are working to develop drugs for fast neutron therapy based on solid-state HA modification with Boron, Gold and Platinum to be used in cancer treatments.
In January 2012, we published a book titled "Hyaluronic Acid" with collected research of V. N. Khabarov, P. Y. Bojkov and M. A. Selyanin. The book contains scientific papers on the subject of chemistry, biology, and use of hyaluronic acid in medicine and additional original materials to tie everything together into a single cohesive work.
The authors sought to cover every angle on the subject, starting with the discovery of hyaluronic acid and its role in living organisms to the process of synthesis of HA, various methods of modification and applications in modern medicine.